IL2 and osteosarcoma: Addressing Tregs’ immunosuppressive influence in osteosarcoma, Kohyama et al. utilized an anti-IL-2 monoclonal antibody, S4B6, to deplete Tregs, eliciting an autologous immune response against osteosarcoma cells, significantly reducing both tumor size and lung metastases, underlining the importance of Tregs reduction in amplifying osteosarcoma’s immune response and its antitumor impact (Kohyama et al., 2012).